Monitoring blood glucose levels is a cornerstone of effective diabetes management, and continuous glucose monitoring (CGM) systems have revolutionized the ability of patients and clinicians to track glucose trends in real time. For the millions of individuals living with diabetes, maintaining sensor accuracy, adhesion, and comfort is essential for achieving glycemic targets and preventing long-term complications. However, a significant subset of patients faces a compounding challenge: the presence of skin infections or wounds at sensor sites. These dermatological complications create a complex clinical scenario where the tools designed to improve glucose control become compromised by the very skin conditions they must interact with. From inflamed diabetic ulcers to superficial bacterial infections, the integrity of the sensor-skin interface is critical, and any disruption carries consequences for data reliability, patient adherence, and overall health outcomes. This article explores the multifaceted challenges of tracking blood glucose in patients with compromised skin, provides evidence-based strategies for overcoming these barriers, and highlights emerging technologies that promise to bridge the gap between dermatological health and precise metabolic monitoring.

The Intersection of Diabetes Management and Dermatological Complications

Diabetes is a systemic disease that profoundly affects the integumentary system. Poor glycemic control, peripheral neuropathy, and vascular insufficiency predispose diabetic patients to a range of skin problems, including bacterial and fungal infections, diabetic dermopathy, and chronic wounds such as diabetic foot ulcers. The prevalence of skin complications in diabetes is substantial, with some estimates suggesting that up to one-third of all diabetic patients will experience a skin-related issue during their lifetime. When these conditions coincide with the site of a CGM sensor, the stakes rise significantly. The sensor must maintain intimate, stable contact with the skin for up to 14 days or longer, depending on the device. Wounds and infections disrupt this contact through inflammation, exudate, altered tissue architecture, and pain—each of which degrades sensor performance and jeopardizes the quality of glucose data. Moreover, the presence of a foreign object like a sensor in or near an infected or wounded area can exacerbate local inflammation, delay healing, and increase the risk of secondary infection. This bidirectional relationship requires careful management, as the benefits of continuous monitoring must be balanced against the risks of dermatological harm.

Key Challenges in Glucose Monitoring with Compromised Skin

Sensor Adhesion and Stability Issues

The adhesion of a CGM sensor to the skin is a function of both the adhesive technology used and the condition of the underlying skin. In the presence of wounds or infections, the skin surface becomes irregular, moistened by exudate, or covered with dressings. Inflammation causes edema, which can lift the sensor away from the skin, creating gaps that reduce adhesion. Sweating, a common compensatory mechanism in areas of inflammation, further undermines adhesive performance. When a sensor partially or fully detaches, it no longer samples interstitial fluid reliably, leading to gaps in data, erroneous readings, and false alarms. Patients may apply additional medical tape or over-bandages to secure the sensor, but these interventions carry their own risks, including skin maceration, allergic contact dermatitis, and difficulty in removing the sensor without trauma. The resulting cycle of poor adhesion, supplemental taping, and skin irritation can become a significant barrier to continued CGM use, especially among elderly or frail patients with delicate skin.

Inflammatory Interference with Sensor Accuracy

Beyond adhesion, inflammation fundamentally alters the local biochemical environment in which the sensor operates. CGM devices measure glucose in the interstitial fluid, which is in dynamic equilibrium with blood glucose. However, acute inflammation triggers a cascade of cellular and molecular events—increased capillary permeability, local edema, and recruitment of immune cells—that can disrupt this equilibrium. Neutrophils and macrophages consume glucose at an accelerated rate during the respiratory burst that accompanies infection, potentially creating a local gradient where interstitial glucose levels are artificially depressed relative to systemic blood glucose. Conversely, the breakdown of tissue and release of cellular contents can introduce interfering substances that affect the sensor's enzymatic or electrochemical detection mechanism. The result is often a pattern of readings that are erratic, delayed, or systematically biased. This phenomenon is particularly problematic in patients with diabetic foot ulcers, where the proximity of the sensor to an inflamed wound can produce readings that do not reflect the patient's true metabolic state, leading to inappropriate insulin dosing and unsafe glucose excursions.

Infection Risk Amplification

Placing a sensor on or near an existing wound or infected site raises concerns about exacerbation of the infection. The sensor's insertion needle creates a micro-channel through the epidermis, providing a potential entry route for bacteria into deeper tissues. The sensor itself, along with any adhesive or dressing materials, can act as a nidus for biofilm formation—a structured community of bacteria encased in a protective matrix that resists both antibiotics and host immune defenses. Once established, a biofilm on a sensor surface can lead to persistent local infection and may even seed systemic infection in immunocompromised patients. Healthcare providers must therefore weigh the metabolic need for continuous glucose data against the infectious risk posed by sensor placement. In settings such as hospitalized patients with sepsis or individuals with poorly controlled diabetic ulcers, alternative monitoring strategies may be necessary until the skin barrier is restored.

Pain and Discomfort Considerations

Chronic wounds and infections are inherently painful conditions, and the addition of a sensor insertion site can amplify discomfort considerably. The mechanical pressure of the sensor housing on tender, inflamed tissue, the pulling sensation from adhesive removal during changes, and the potential for nerve irritation all contribute to a negative patient experience. Pain is a powerful driver of non-adherence; patients may avoid sensor changes, remove sensors prematurely, or abandon CGM altogether in favor of less frequent but painful fingerstick monitoring. This is particularly concerning because adequate glucose monitoring is essential for wound healing itself—hyperglycemia impairs immune function and delays tissue repair, while hypoglycemia can be life-threatening. A cycle can develop in which pain leads to poor monitoring, which leads to poor glycemic control, which perpetuates the wound and infection, thereby causing more pain. Breaking this cycle requires deliberate attention to patient comfort, including the use of topical anesthetics, alternative sensor locations, and communication strategies that acknowledge the sensory burden of device use.

Physiological Mechanisms Behind Sensor Interference

Altered Interstitial Fluid Composition

Interstitial fluid is the medium through which CGM sensors measure glucose, but it is not a static matrix. In the presence of inflammation or infection, the composition of interstitial fluid changes significantly. Pro-inflammatory cytokines such as interleukin-6 and tumor necrosis factor-alpha increase vascular permeability, allowing large molecules—including plasma proteins and cellular debris—to enter the interstitial space. These substances can coat the sensor's working electrode, a process known as biofouling, which impairs the sensor's ability to detect glucose accurately. Furthermore, the acidic environment of infected tissue alters the pH of interstitial fluid, which can shift the equilibrium of the glucose oxidase reaction used by many enzymatic sensors. Calibration algorithms assume a relatively stable local environment, but in compromised skin, this assumption no longer holds. The resulting measurement error can be unpredictable in magnitude and direction, making it difficult for clinicians to trust CGM data when managing acute illness or chronic wounds.

Microcirculatory Changes

The microcirculation of the skin is profoundly affected by both diabetes and local infection. Diabetic microangiopathy leads to thickening of capillary basement membranes and reduced capillary density, impairing the exchange of glucose between blood and interstitial fluid. When a wound or infection is present, local vasodilation and increased capillary permeability occur as part of the inflammatory response, but these changes are superimposed on a background of diabetic microvascular dysfunction. The net effect can be a dissociation between blood glucose and interstitial fluid glucose that is both larger and more variable than in healthy skin. Studies using microdialysis techniques have demonstrated that the time lag between blood glucose changes and interstitial fluid glucose changes can be significantly prolonged in inflamed tissue, sometimes exceeding 30 minutes. For a patient relying on a CGM to detect hypoglycemia, such a delay could be dangerous, particularly during sleep or when driving. Understanding these microcirculatory dynamics is crucial for interpreting CGM data from suboptimal sensor sites.

Biofouling and Sensor Surface Contamination

Exudate from wounds contains a complex mixture of proteins, inflammatory cells, bacteria, and enzymes that can directly interfere with sensor function. As exudate dries and accumulates on the sensor surface, it forms a physical barrier that impedes glucose diffusion to the detection membrane. Proteins such as albumin and fibrinogen adsorb onto the sensor surface within minutes of exposure, and cellular debris from necrotic tissue can create similar problems. This biofouling effect is especially problematic for long-duration sensors, where the accumulation of material over days can cause a progressive decline in signal quality. Some newer sensors incorporate anti-fouling coatings or hydrophilic membranes designed to resist protein adsorption, but these technologies are not universally effective against the aggressive biological milieu of infected wounds. In practice, patients and clinicians must be vigilant about signal deterioration and be prepared to replace sensors earlier than the labeled wear period if skin conditions are severe.

Clinical Strategies for Overcoming Monitoring Obstacles

Comprehensive Wound Care Protocols

The foundation of successful glucose monitoring in patients with skin infections or wounds is proper wound management. Before any sensor is placed, the wound should be assessed for signs of infection, size, depth, and exudate level. Standard wound care principles—cleansing, debridement, infection control, and moisture balance—must be applied consistently. For infected wounds, culturing and targeted antibiotic therapy are essential. Once the wound is clean and controlled, the surrounding skin should be prepared for sensor placement. This includes gentle cleansing with a non-irritating skin prep, thorough drying, and the application of barrier films or wipes that create a protective layer between the adhesive and the skin. Commercial skin barrier products containing acrylate copolymers or dimethicone can significantly reduce irritation and improve adhesion. In patients with chronic exudate, absorbent dressings placed around the sensor site can wick moisture away from the adhesive edge, prolonging sensor life. The key is to integrate sensor management into the existing wound care regimen rather than treating them as separate tasks.

Sensor Placement Optimization

When a wound or infection is present at the usual sensor site, the first consideration should be whether an alternative location is available. Approved CGM sensor sites include the abdomen, upper arm, thigh, and gluteal region, depending on the device. In patients with abdominal wounds or diabetic foot ulcers, the upper arm or thigh often provides healthy skin that is distant from the affected area. However, caution is needed: the upper arm may have less subcutaneous tissue, and the thigh may be subject to movement artifacts from clothing or activity. Rotating sensor sites methodically and documenting which sites work well for a given patient can prevent recurrent problems. If no healthy site is available, or if the patient requires data from a site near the wound for clinical reasons, sensors can be placed adjacent to—but not directly over—the wound edge. A distance of at least 2 to 3 centimeters from the wound margin is generally recommended to avoid the zone of active inflammation while still providing representative interstitial fluid sampling. In all cases, the sensor should be secured with hypoallergenic tape or a silicone-based adhesive if the patient has a history of adhesive allergy.

Leveraging Alternative Monitoring Modalities

In situations where CGM data is unreliable or contraindicated due to skin integrity issues, alternative monitoring approaches become necessary. Fingerstick blood glucose monitoring remains the gold standard for accuracy and is not affected by skin infections at the sensor site, as the puncture site is fresh for each test. For patients who require frequent data—particularly those on intensive insulin therapy or at high risk for hypoglycemia—a regimen of eight to ten fingerstick checks per day may be needed temporarily. Emerging non-invasive technologies, such as infrared spectroscopy and reverse iontophoresis, are being developed for glucose monitoring through intact skin, but these are not yet widely available for clinical use. Another practical approach is "flash glucose monitoring," which uses a sensor that must be scanned by the patient to obtain a reading; since the sensor stores historical data, even if interstitial fluid dynamics are altered, the trends may still be informative when interpreted by an experienced clinician. The choice of modality should be individualized based on the patient's glycemic targets, cognitive function, visual acuity, and manual dexterity.

Pharmacological Considerations

Medications used to manage wound infections and the inflammatory response can themselves affect glucose metabolism and sensor performance. Systemic glucocorticoids, often prescribed for severe inflammation or auto-immune comorbidities, cause significant hyperglycemia and can alter the relationship between blood and interstitial glucose. Antibiotics, particularly fluoroquinolones and some beta-lactams, have been associated with both hyperglycemia and hypoglycemia in diabetic patients. Topical agents applied to the wound, such as silver sulfadiazine or medical honey, may migrate onto the sensor surface and interfere chemically with the glucose detection reaction. Clinicians must review all topical and systemic medications when interpreting CGM data from a patient with an infected or wounded sensor site. Adjustments to insulin dosing or sensor calibration algorithms may be necessary during periods of pharmacotherapy. If interference is suspected, a paired comparison of CGM readings with simultaneous fingerstick measurements can help quantify the error and guide decision-making.

Emerging Technologies and Future Directions

The medical device industry is actively working to address the challenges posed by compromised skin. Next-generation CGM sensors are being designed with advanced adhesives that incorporate antimicrobial agents, such as silver ions or chlorhexidine, to reduce infection risk directly at the insertion site. Flexible, biocompatible substrates that conform more gently to irregular skin surfaces are in development, reducing the mechanical mismatch between the sensor and inflamed tissue. Researchers are also exploring "smart" wound dressings that integrate glucose sensing capabilities directly into the dressing material, allowing for simultaneous wound monitoring and glycemic tracking. These dual-function devices could be particularly valuable for patients with diabetic foot ulcers, where both wound healing and glycemic control are critical. On the software side, machine learning algorithms are being trained to detect patterns in CGM data that are indicative of local biofouling or inflammation, prompting the user or provider to change the sensor or recalibrate before data quality degrades. As these technologies mature, the clinical dogma that CGM is unsuitable for patients with skin lesions will likely be overturned, replaced by a more nuanced approach that tailors device selection and site management to the individual's dermatological status.

Practical Guidance for Patients and Caregivers

For patients living with diabetes who also manage skin infections or chronic wounds, proactive self-care is essential. Daily inspection of the sensor site for redness, swelling, warmth, or discharge should become a routine habit. Signs of infection warrant immediate medical attention and removal of the sensor, even if it means a loss of data. Using a medical ID or tracking sheet to record sensor site appearances alongside glucose readings can help clinicians identify correlations between skin health and data accuracy. Patients should be empowered to ask their healthcare provider for alternative sensor locations or specific skin prep products covered by insurance. Caregivers assisting elderly or immobile patients should be trained in proper skin hygiene and gentle adhesive removal techniques, such as using adhesive remover wipes or warm water compresses to minimize trauma. Support groups and online communities for diabetes management can be valuable resources for practical tips on managing sensor adhesion and discomfort, though medical advice from healthcare professionals should always take precedence. Ultimately, the goal is to maintain continuous glucose monitoring for as long as it benefits the patient, using a flexible, adaptive approach that accommodates the reality of skin complications.

Conclusion

Tracking blood glucose in patients with skin infections or wounds at sensor sites presents a genuine clinical challenge that intersects dermatology, endocrinology, and medical technology. The interplay between altered skin physiology, inflammation, infection risk, and sensor function demands a thoughtful, individualized strategy that goes beyond standard CGM guidelines. By understanding the mechanisms that degrade sensor accuracy—including biofouling, altered interstitial fluid dynamics, and microcirculatory changes—clinicians can better interpret data and anticipate errors. Practical measures such as meticulous wound care, strategic sensor placement, and judicious use of alternative monitoring modalities can preserve the benefits of continuous monitoring even in difficult circumstances. Emerging technologies promising antimicrobial adhesives, flexible substrates, and integrated wound-sensing dressings offer hope for a future where skin health and glucose monitoring are not competing priorities. For now, the burden falls on healthcare providers to educate themselves and their patients about the specific challenges of monitoring with compromised skin, and to remain flexible in their approach. The ultimate goal remains clear: accurate, consistent, and safe glucose data that empowers patients to manage their diabetes effectively, regardless of the condition of their skin.